

Dan G. Duda, D.M.D., Ph.D.,

Director of Translational Research in GI Radiation Oncology

Associate Investigator, Massachusetts General Hospital Research Institute

Associate Professor, Harvard Medical School

Boston, MA

Dan G. Duda graduated in 1993 with a DMD from the University of Iasi, Romania, and earned his PhD in GI Surgery in 2001 from Tohoku University Graduate School of Medicine, Sendai, Japan. In 2001, he joined the Steele Laboratories in the Department of Radiation Oncology at Massachusetts General Hospital and Harvard Medical School, where he rose through the ranks to Associate Professor of Tumor Biology in 2012. His current efforts focus on translational research on the interaction of locally derived stroma (tumor-associated vessels, fibroblasts) and distant stroma (inflammatory cells) with cancer cells during tumor progression. The goal is to use this knowledge for the development of predictive biomarkers for targeted therapies for malignant diseases. While these studies include multiple tumor types, the main areas of focus are new therapies for metastatic or advanced pancreatic and liver cancers, which remain intractable diseases.

He has authored so far over 160 publications, of which 91 are original reports, including in *Nature*, *Nature Medicine*, *Nature Genetics*, *Cell*, *Cancer Cell*, *Proceedings of the National Academy of Sciences USA* and *Journal of Clinical Oncology*. He has been invited to present these studies at more than 120 local, national and international meetings in USA, Europe, Asia and Australia, including as a plenary speaker and as a keynote speaker. For his work, Dr. Duda received multiple honors and awards, including from the Cancer Research Institute (2002), American Association for Cancer Research (2001 and 2005), International Association of Surgeons, Gastroenterologists and Oncologists (2014), Massachusetts General Hospital (2015) and Granara-Skerry Trust (2016). He is an Honorary Member of the Academy of Medical Sciences of Romania since 2012. He has served as a panel member for multiple scientific expert meetings worldwide. US National Cancer Institute, Massachusetts General Hospital ECOR, Andrew L. Warshaw, MD, Institute for Pancreatic Cancer and The Samuel Singer Brown Fund for Pancreatic Ductal Adenocarcinoma Research, as well as by partnerships with Industry (Merrimack Pharma and HealthCare Pharma). He has been the Head of the International Association of Surgeons, Gastroenterologists and Oncologists Cancer Research Section since 2013, and became Secretary General of the International Association of Surgeons, Gastroenterologists and Oncologists in 2015. In 2016, he was appointed as the Director of Translational Research in Gastrointestinal Cancer in the Department of Radiation Oncology at Massachusetts General Hospital Cancer Center.